3-Fluoropiperidin-4-ol hydrochloride | 1356339-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-Fluoropiperidin-4-ol hydrochloride
• 英文别名: 3-fluoropiperidin-4-ol;hydrochloride
• CAS: 1356339-27-9
• 化学式: C5H11ClFNO
• 分子量: 155.6
• InChiKey: VGRYZBPWUNRGDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
  申请人：Abbvie Deutschland GmbH & Co. KG

  公开号：US20170260158A1

  公开（公告）日：2017-09-14

  The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT 6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT 6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT 6 receptor.

  本发明涉及公式I的喹啉化合物，其中变量的定义如索引和描述中所述。本发明还涉及含有这种化合物的药物组合物，以及它们作为5-HT6受体调节剂的用途，用于制备用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的药物，以及用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的方法。
• Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
  申请人：Abbvie Deutschland GmbH & Co. KG

  公开号：US10160744B2

  公开（公告）日：2018-12-25

  The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.

  本发明涉及式 I 的喹啉化合物 其中变量的定义见权利要求和说明。本发明还涉及一种含有此类化合物的药物组合物、它们作为 5-HT6 受体调节剂的用途、它们用于制备预防或治疗对 5-HT6 受体调节有反应的病症和紊乱的药物的用途，以及预防或治疗对 5-HT6 受体调节有反应的病症和紊乱的方法。
• DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2010506A1

  公开（公告）日：2009-01-07
• N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE
  申请人：AbbVie Overseas S.à r.l.

  公开号：EP3359541B1

  公开（公告）日：2020-08-05
• US7632829B2
  申请人：——

  公开号：US7632829B2

  公开（公告）日：2009-12-15